Flag of the European Union EU Clinical Trials Register Help

Clinical trials for fluoxetine

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    74 result(s) found for: fluoxetine. Displaying page 3 of 4.
    « Previous 1  2  3  4  Next»
    EudraCT Number: 2007-007166-37 Sponsor Protocol Number: TECHUB2007 Start Date*: 2009-02-04
    Sponsor Name:MIKEL URRETAVIZCAYA SARACHAGA
    Full Title: “TERAPIA ELECTROCONVULSIVA DE CONSOLIDACIÓN ASOCIADA A PSICOFÁRMACOS VERSUS FARMACOTERAPIA EN LA PREVENCIÓN DE RECIDIVAS EN EL TRASTORNO DEPRESIVO MAYOR. UN ENSAYO CLÍNICO, PRAGMÁTICO, PROSPECTIVO ...
    Medical condition: TRASTORNO DEPRESIVO MAYOR
    Disease: Version SOC Term Classification Code Term Level
    9.1 10025453 Major depressive disorder NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-002731-28 Sponsor Protocol Number: P12-01/BP1.4979 Start Date*: 2013-03-01
    Sponsor Name:Bioprojet
    Full Title: Randomized placebo controlled trial assessing the efficacy and safety of BP1.4979 in smoking cessation
    Medical condition: Smoking cessation
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004869 10008374 Cessation of smoking LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2011-005179-18 Sponsor Protocol Number: RGH-MD-75 Start Date*: 2012-03-12
    Sponsor Name:Forest Research Institute, Inc
    Full Title: A Double-blind, Placebo-controlled Study of Cariprazine (RGH-188) as Adjunctive Therapy In Major Depressive Disorder.
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004873 10025463 Major depressive disorder, single episode LLT
    14.1 100000004873 10025454 Major depressive disorder, recurrent episode LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed) EE (Completed) SK (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2015-001220-31 Sponsor Protocol Number: RISAUT4002 Start Date*: 2015-03-31
    Sponsor Name:Johnson & Johnson Pharmaceutical Research and Development, L.L.C.
    Full Title: Risperidone in the Treatment of Children and Adolescents With Autistic Disorder: A Double-Blind, Placebo-Controlled Study of Efficacy and Safety, Followed by an Open-Label Extension Study of Safety
    Medical condition: Autistic disorder
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004852 10003808 Autistic disorder LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2007-002130-11 Sponsor Protocol Number: DEPRES-07 Start Date*: 2008-02-25
    Sponsor Name:Fundació de l'Institut de Recerca HSCSP
    Full Title: Estrategias terapéuticas en Trastorno Depresivo Mayor resistente a tratamiento con Inhibidores Selectivos de la Recaptación de la Serotonina. Ensayo clínico pragmático, paralelo, aleatorizado con e...
    Medical condition: Pacientes con depresión mayor resistente a Inhibidores Selectivos de la Recaptación de serotonina.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10057840 Major depression LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-000358-23 Sponsor Protocol Number: CMS-001 Start Date*: 2019-02-06
    Sponsor Name:CATALYST PHARMACEUTICALS INC.
    Full Title: A phase 3, multicenter, double-blind, placebo-controlled, randomized, outpatient two-period two-treatment crossover study to evaluate the efficacy and safety of amifampridine phosphate (3,4 diamino...
    Medical condition: Congenital myasthenic syndromes
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10028424 Myasthenic syndrome PT
    20.0 10029205 - Nervous system disorders 10028425 Myasthenic syndromes in diseases classified elsewhere LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-021044-17 Sponsor Protocol Number: CLOCK_depression Start Date*: 2010-08-11
    Sponsor Name:Medizinische Universität Wien
    Full Title: The effect of agomelatine on CLOCK gene expression in patients with major depressive disorder and healthy controls: an exploratory study.
    Medical condition: Major depressive disorder (MDD), Seasonal affective disorder (subtype of MDD)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10012378 Depression LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-001966-40 Sponsor Protocol Number: CD001 Start Date*: 2014-01-27
    Sponsor Name:Companion Diagnostics BV
    Full Title: A double blind, randomized, placebo controlled, cross-over, Lybridos dose finding study to validate the predictive power of the diagnostic model for Lybrido and Lybridos efficacy and to identify an...
    Medical condition: Hypoactive Sexual Desire Disorder/SSRI-induced sexual dysfunction
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004873 10040470 Sexual desire disorders HLT
    14.1 100000004873 10020933 Hypoactive sexual desire disorder LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-003251-37 Sponsor Protocol Number: ACP-103-054 Start Date*: 2019-06-11
    Sponsor Name:ACADIA Pharmaceuticals Inc
    Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate R...
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004873 10025454 Major depressive disorder, recurrent episode LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) SK (Prematurely Ended) PL (Prematurely Ended) FI (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-002577-22 Sponsor Protocol Number: COMP003 Start Date*: Information not available in EudraCT
    Sponsor Name:COMPASS Pathfinder, Limited
    Full Title: The safety and efficacy of psilocybin as an adjunctive therapy in participants with treatment-resistant depression
    Medical condition: treatment resistant depression
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004873 10025454 Major depressive disorder, recurrent episode LLT
    21.1 100000004873 10025463 Major depressive disorder, single episode LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-001737-15 Sponsor Protocol Number: D1449C00009 Start Date*: 2005-07-18
    Sponsor Name:NV AstraZeneca SA
    Full Title: An open-label, non-comparative, multi-centre, phase II prospective trial to assess the efficacy of Quetiapine fumarate augmentation of selective serotonin reuptake inhibitors (SSRIs) in SSRI-resist...
    Medical condition: The medical condition being treated by this protocol is single or recurrent major depressive disorder (MDD), not responding to at least one adequate SSRI treatment, however, the patients being trea...
    Disease: Version SOC Term Classification Code Term Level
    8.0 10025453
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2021-001192-17 Sponsor Protocol Number: ITI-007-501 Start Date*: 2021-11-24
    Sponsor Name:Intra-Cellular Therapies, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Assess the Efficacy and Safety of Lumateperone as Adjunctive Therapy in the Treatment of Patients with Major Depressive Disorder
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10025458 Major depressive disorder, recurrent episode, moderate degree LLT
    21.1 100000004873 10081270 Major depressive disorder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) SK (Completed) BG (Completed) HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-005860-69 Sponsor Protocol Number: ODEN Start Date*: 2021-05-10
    Sponsor Name:University of Gothenburg
    Full Title: OSU6162 as add-on in SSRI/SNRI-resistant depression (ODEN): a double-blind, placebo-controlled evaluation of efficacy and safety.
    Medical condition: Depression
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-003073-33 Sponsor Protocol Number: MYL-1603N-3001 Start Date*: 2023-03-08
    Sponsor Name:Mylan Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Compare the Anti-Depressive Efficacy and Safety of Samyr® Tablet versus Placebo Tablet on top of Adjunctive Ant...
    Medical condition: Major Depression Disorder
    Disease: Version SOC Term Classification Code Term Level
    21.1 10037175 - Psychiatric disorders 10057840 Major depression PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-003984-24 Sponsor Protocol Number: EPIsoDE_01 Start Date*: 2020-11-17
    Sponsor Name:Central Institute of Mental Health
    Full Title: A phase II randomized, double-blind, active placebo-controlled parallel group trial to examine the efficacy and safety of psilocybin in treatment-resistant major depression
    Medical condition: Treatment-Resistant Depressive Episode or Treatment-Resistant Recurrent Depressive Disorder of moderate to severe degree withoutpsychotic features
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-001212-29 Sponsor Protocol Number: ITI-007-502 Start Date*: 2022-01-23
    Sponsor Name:Intra-Cellular Therapies, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Assess the Efficacy and Safety of Lumateperone as Adjunctive Therapy in the Treatment of Patients with Major Depressive Disorder
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10025458 Major depressive disorder, recurrent episode, moderate degree LLT
    21.1 100000004873 10081270 Major depressive disorder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) BG (Completed) SE (Completed) FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-003867-13 Sponsor Protocol Number: CL2-47445-014 Start Date*: 2016-02-15
    Sponsor Name:Institut de Recherches internationales Servier
    Full Title: Efficacy and safety of S 47445 versus placebo as adjunctive treatment of Major Depressive Disorder in patients with an inadequate response to antidepressant therapy. A randomised, double-blind, pla...
    Medical condition: Major depressive disorder
    Disease: Version SOC Term Classification Code Term Level
    19.0 10037175 - Psychiatric disorders 10057840 Major depression PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) FI (Completed) SK (Completed) CZ (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2013-004881-33 Sponsor Protocol Number: 73-05-3832-397285-12 Start Date*: 2017-02-28
    Sponsor Name:Universitätsklinikum Würzburg
    Full Title: Pharmacovigilance in children and adolescents: clinical trial protocol, subproject 1: Large Simple Trial, IIIb on the (off-label-) use of antidepressants and antipsychotics
    Medical condition: therapeutic use in clinical practise
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-002675-27 Sponsor Protocol Number: 31-07-246 Start Date*: 2009-05-11
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc.
    Full Title: A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole (OPC-14597) as Ma...
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039626 Schizophrenia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BG (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2006-004783-31 Sponsor Protocol Number: D3690C00007 Start Date*: 2007-02-02
    Sponsor Name:AstraZeneca AB
    Full Title: A Double-Blind, Randomised, Parallel-Group, Placebo-Controlled, MultiCentre, Phase IIa Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Multiple Oral Dos...
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    8.1 10039626 Schizophrenia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) LV (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Jun 05 22:36:39 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA